41 – 50 of 95
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
(
- Contribution to journal › Article
-
Mark
Nonablative neonatal bone marrow transplantation rapidly reverses severe murine osteopetrosis despite low level engraftment and lack of selective expansion of the osteoclastic lineage.
(
- Contribution to journal › Article
-
Mark
Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice
(
- Contribution to journal › Article
-
Mark
Canonical BMP signaling is dispensable for hematopoietic stem cell function in both adult and fetal liver hematopoiesis, but essential to preserve colon architecture.
(
- Contribution to journal › Article
-
Mark
CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
(
- Contribution to journal › Article
- 2009
-
Mark
Development of Novel Therapies in Murine Models for Gaucher Disease
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
In mantle cell lymphoma (MCL) the MCL-International Prognostic Index (MIPI) is a better predictor of event-free and overall survival than International Prognostic Index (IPI) in patients receiving intensive 1st line treatment including ASCT
2009) 14th Annual Meeting of the European-Hematology-Association In Haematologica-The Hematology Journal 94. p.0971-0971(
- Contribution to journal › Published meeting abstract
-
Mark
Successful Low-Risk Hematopoietic Cell Therapy in a Mouse Model of Type 1 Gaucher Disease
(
- Contribution to journal › Article
-
Mark
Neonatal bone marrow transplantation without prior conditioning rapidly reverses osteopetrosis in oc/oc mice despite only minimal donor cell engraftment
(
- Contribution to journal › Published meeting abstract
-
Mark
(90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)
(
- Contribution to journal › Published meeting abstract